Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
POLYCILLIN is an oral chewable tablet formulation of ampicillin/ampicillin trihydrate, a beta-lactam antibiotic used to treat bacterial infections. Ampicillin works by inhibiting bacterial cell wall synthesis, making it effective against a broad spectrum of gram-positive and some gram-negative bacteria. This is a classic broad-spectrum antibiotic indicated for respiratory, urinary, gastrointestinal, and skin infections.
As a pre-launch oral antibiotic, POLYCILLIN represents an early-stage opportunity with potential team growth contingent on regulatory approval and market adoption in a competitive generic-heavy segment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on POLYCILLIN offers exposure to antibiotic commercialization, formulation differentiation, and regulatory execution in a pre-launch setting. However, the established nature of ampicillin and competitive generic landscape mean career growth is limited compared to novel therapeutic launches.
Worked on POLYCILLIN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.